An analysis of more than 8000 patients with HIV and hypertension suggests these patients may not be receiving the most efficacious antihypertensive agents and this could be placing these patients at increased risk of cardiovascular disease events or death.
The US FDA has granted a second approval to treprostinil (Tyvaso) inhalation solution, this time for the treatment of patients pulmonary hypertension associated with interstitial lung disease (PH-ILD) to help improve exercise ability.
Results of the phase 2 PULSAR trial indicate sotatercept could be an effective adjunct to background medical therapy for reducing pulmonary vascular resistance in patients with pulmonary arterial hypertension.
A systematic review and meta-analysis of data from more than 280 studies is providing insight into the potential increase in risk of depression and other psychiatric adverse events associated with beta-blockers.
An analysis of data from more than 16k Hispanic/Latino individuals indicates the prevalence of cardiovascular risk factors among those with a history of stroke/TIA was greater than previously thought and many are unaware of these risk factors.
An analysis using data from the CDC, COVID-NET, and the COVID Tracking Project suggests nearly 2 out of 3 COVID-19 hospitalizations in the US were attributable to obesity, hypertension, diabetes, and heart failure.
An analysis of data from the International Consortium of Blood Pressure-Genome Wide Association Studies suggests every 1 mmHg increase in blood pressure was linked to a 1.4-2.6% increase in risk of atrial fibrillation.